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Chronic renal disease is characterized by declining renal
function, loss of intrinsic renal cells, and their replacement
with fibrotic tissue. This study investigates apoptosis and its
regulation in the context of chronic renal disease. RNA was
extracted from renal biopsies from patients with various
forms of chronic renal disease. Expression of genes of the
Bcl-2 family, death receptor pathway, and growth factors
were measured by reverse-transcription real-time polymerase
chain reaction. Apoptosis was detected by the terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick
end-labeling technique. Tubulointerstitial apoptosis was
positively associated with tubulointerstitial injury and renal
dysfunction and increased 2.3-fold per unit (U) increase in
transforming growth factor b1 (TGFb1) mRNA (Po0.05).
Conversely, a 1 U increase in epidermal growth factor (EGF)
mRNA was associated with a 47% decrease in
tubulointerstitial apoptosis (Po0.05). Tubulointerstitial injury
was correlated with increased TGFb1 and tumour necrosis
factor a (TNFa) mRNA (Po0.005) and decreased EGF mRNA
(Po0.05). Additionally, for a 10 U decrease in the glomerular
filtration rate there was an estimated increase of 5 and 10%
in TGFb1 and TNFa mRNA, respectively (Po0.05), whereas
EGF mRNA decreased by an estimated 15% (Po0.005).
Therefore dysregulation of cytokine/growth factor expression
plays a central role in the progression of chronic renal
disease through contribution to renal cell loss,
tubulointerstitial injury, and renal dysfunction.
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Recent studies have demonstrated that between 11 and 16%
of the adult population display signs of kidney disease,1,2 and
the worldwide incidence of End Stage Renal Disease (ESRD)
is growing at approximately 8% per year.3 To reduce the
burden of chronic renal disease, it is imperative that we
obtain a better understanding of the processes linked to the
progression of renal disease.
A common feature of chronic renal diseases of varying
etiologies is the loss of intrinsic renal cells through apoptosis,
associated with a decrease in renal function. Increased
apoptosis has been demonstrated to contribute to tubular
atrophy, glomerulosclerosis, and interstitial scarring in
various types of chronic renal disease including IgA
nephropathy, lupus nephritis, and focal and segmental
glomerulosclerosis.4–10
Apoptosis is an evolutionally conserved, tightly controlled
mechanism of cellular suicide. Apoptotic signals are mediated
through the extrinsic death receptor pathway, the intrinsic
mitochondrial pathway, or a combination of the two. Death
receptors are members of the tumour necrosis factor/nerve
growth factor (TNF/NGF) superfamily of cell surface
receptors and include Fas and TNF receptor 1 (TNFR1),11,12
which bind to Fas ligand (FasL) and TNFa, respectively. The
binding of the ligand to the receptor results in the
recruitment of cytosolic adaptor molecules and ultimately
the activation of a cascade of intracellular proteases called
caspases. The intrinsic pathway of apoptosis is regulated by
the Bcl-2 (B-cell lymphoma/leukaemia protein-2) family of
proteins, which contains both antiapoptotic (e.g. Bcl-2, Bcl-
xL, A1, Bcl-w) and proapoptotic (Bax, Bak, Bad, Bid, Bim)
members.13,14 The antiapoptotic members form heteromers
with the proapoptotic members, preventing their activation
and/or insertion into the mitochondrial outer membrane.
This inhibits the subsequent release of proapoptotic mole-
cules from the mitochondrial inter-membrane space and the
initiation of the caspase cascade.15–17 Thus the balance
between the pro- and antiapoptotic proteins impacts greatly
on the fate of the cell.
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Many growth factors are involved in either initiation or
suppression of apoptosis. Insulin-like growth factor-1 (IGF-
1) and epidermal growth factor (EGF) protect renal cells in
vitro from apoptotic stimuli such as serum deprivation18–20
and Fas-induced apoptosis.19,21 In contrast transforming
growth factor b1 (TGFb1) and TNFa have been shown to
induce apoptosis in renal fibroblasts,19 tubular epithelial
cells,22,23 mesangial cells,24,25 and glomerular epithelial
cells.26,27
In this study, we investigate the hypothesis that altered
expression of genes influencing apoptosis in chronic renal
disease contributes to clinical injury and renal dysfunction
through increased tubulointerstitial apoptosis. This associa-
tion between apoptosis and renal disease is explored further
in relation to patient outcome in biopsies from patients with
IgA nephropathy.
RESULTS
Association between tubulointerstitial apoptosis and
markers of chronic renal disease
Tubulointerstitial apoptosis was rare in control tissue. In
patient biopsies, however, there was a large degree of
variation in the number of apoptotic cells detected within
the tubulointerstitium, with an increase evident in most, but
not all biopsies (Figure 1). As the severity of tubulointerstitial
injury increased so too did the number of terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick
end-labeling (TUNEL)-positive cells (Po0.05, Figure 2).
Examples of TUNEL-positive tubulointerstitial cells are
shown in Figure 3.
The number of TUNEL-positive cells in the tubulointer-
stitium was also strongly positively correlated with renal
dysfunction and proteinuria. A decrease in 10 U of the
estimated glomerular filtration rate (eGFR) was associated
with an estimated increase of 15% in TUNEL-positive
tubulointerstitial cells per mm2 (95% confidence interval
(CI): 8–21%, Po0.0001). Similarly, an increase of 1 g/day in
proteinuria was associated with an estimated increase of 16%
in TUNEL-positive tubulointerstitial cells per mm2 (95% CI:
8–25%, Po0.0001).
Glomerular apoptosis was not a consistent feature;
however, low levels of TUNEL-positive cells were detected
in up to 80% of glomeruli in LN, 50% in IgAN and
occasionally in other biopsies (Table 1). There were no
statistically significant differences between groups.
Expression of genes influencing apoptosis in different types
of chronic renal disease
Both Fas and FasL mRNA concentration was increased in all
patient groups as compared to controls (Po0.05, Figure 4
and Table 2). Comparison between the different forms of
chronic renal disease did not demonstrate consistent changes
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Figure 1 | The number of tubulointerstitial apoptotic cells
is elevated in chronic renal disease. Apoptosis was detected in the
tubulointerstitium of patient biopsies using the TUNEL technique and
was found to be increased in most, but not all, biopsies as compared
to controls. The mean of each group is represented by a red line.
Abbreviations: TMN, thin membrane nephropathy; IgAN, IgA
nephropathy; HTN, hypertensive nephropathy; CsAN, cyclosporine A
nephropathy; FSGS, focal and segmental glomerulosclerosis;
LN, lupus nephritis.
Figure 2 | Apoptosis in the tubulointerstitium progressively
increases with the severity of tubulointerstitial injury.
Tubulointerstitial apoptotic cells were detected using the TUNEL
technique. The number of apoptotic cells was increased significantly
between each grade of severity of tubulointerstitial injury. The mean
is represented by a red line.
Figure 3 | Examples of TUNEL-positive tubulointerstitial cells in
chronic renal disease. (a) TUNEL-positive interstitial cells in a renal
biopsy from a hypertensive nephropathy patient, original
magnification  1000. (b) TUNEL-positive tubular cell in a renal
biopsy from a focal and segmental glomerulosclerosis patient,
original magnification  1000.
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in the expression of proapoptotic (Bax, Bad) or antiapoptotic
(Bcl-2, Bcl-xL) members of the Bcl-2 family, except for
proapoptotic Bid, which was increased compared to controls
(Table 2).
Analysis of the expression of growth factors showed that
the mRNA concentration of IGF-1 was upregulated in
chronic renal disease as compared to controls (Table 3). In
contrast, EGF mRNA was markedly decreased in cyclosporine
A nephropathy versus controls (Po0.05) and a trend toward
decreased EGF mRNA was evident in hypertensive nephro-
pathy (P¼ 0.06). No significant differences were evident
between groups for TNFa or TGFb1 (Table 3).
Association between tubulointerstitial apoptosis and the
expression of genes influencing cell death
As evident in Table 4, the number of TUNEL-positive
tubulointerstitial cells was positively associated with TGFb1
mRNA concentration, with a 2.30-fold increase in apoptosis
per unit increase in TGFb1 mRNA (Po0.05). There was also
evidence of a negative relationship between tubulointerstitial
apoptosis and the expression of the survival factor EGF, with
a 47% decrease in tubulointerstitial TUNEL-positive cells for
a 1 U increase in EGF mRNA (Po0.05). No significant
associations were evident between the tubulointerstitial
TUNEL score and the other genes assessed.
Association between markers of renal disease and the
expression of genes influencing apoptosis
As no association was identified between the expression of
apoptotic effector/regulatory genes and diagnosis, patient
biopsies were grouped according to the degree of tubulo-
interstitial damage reported by the pathologist (Table 5).
Table 6 summarizes the mean gene expression in each group.
Significant associations between gene expression and tubulo-
interstitial damage were evident for TNFa and TGFb1, which
were increased with the degree of tubulointerstitial injury
(Po0.005), whereas EGF mRNA levels decreased (Po0.05).
No significant associations were evident between the severity
of tubulointerstitial injury and the other genes investigated.
Table 1 | Increased glomerular apoptosis is evident in some
forms of chronic renal disease
Diagnosis
Biopsies with TUNEL-positive
glomerular cells/biopsies
containing glomeruli
Number of TUNEL-positive
cells per glomeruli
(mean7s.e.m.)
Control 1/5 0.0270.02
TMN 4/14 0.1570.11
IgAN 9/18 0.2070.07
HTN 2/9 0.0770.06
CsAN 1/4 0.0570.05
FSGS 2/5 0.2370.16
LN 4/5 0.3670.13
CsAN, cyclosporine A nephropathy; FSGS, focal and segmental glomerulosclerosis;
HTN, hypertensive nephropathy; IgAN, IgA nephropathy; LN, lupus nephritis; TdT,
terminal dexynucleotidyl transferase; TMN, thin membrane nephropathy; TUNEL,
TdT-mediated dUTP nick end-labeling.
Glomerular apoptosis was detected in patient biopsies using the TUNEL technique
and was most evident in IgA nephropathy and lupus nephritis.
Table 2 | The gene expression of apoptotic effector/regulatory molecules is altered in chronic renal disease
Diagnosis
Fas
(mean7s.e.m.)
FasL
(mean7s.e.m.)
Bcl-2
(mean7s.e.m.)
Bcl-xL
(mean7s.e.m.)
Bax
(mean7s.e.m.)
Bad
(mean7s.e.m.)
Bid
(mean7s.e.m.)
Control 0.7670.12 5.0271.95 0.7170.09 0.8870.07 0.8770.06 0.9170.09 0.7770.06
TMN 1.8670.20c 55.5879.73c 0.8270.05 0.8870.05 0.9470.03 1.0770.05 1.5970.18c
IgAN 2.3370.27c 85.64714.53c 0.7070.05 0.7970.07 0.9770.04 1.1070.05 1.8070.19c
HTN 2.4670.24c 47.51710.36c 0.7270.06 0.7670.06 1.0870.07 1.0970.03 1.3170.13b
CSAN 2.4870.69 38.20712.98 0.6870.06 0.8670.06 0.9870.15 1.0170.13 1.3770.29
FSGS 1.6470.43a 30.06714.71a 0.7170.03 0.8670.07 0.8670.16 1.1270.09 1.2270.23
LN 2.1470.42a 71.30720.76b 0.7670.03 0.7570.04 0.9070.05 1.0970.07 1.6370.32
CsAN, cyclosporine A nephropathy; FSGS, focal and segmental glomerulosclerosis; HTN, hypertensive nephropathy; IgAN, IgA nephropathy; LN, Lupus nephritis;
PCR, polymerases chain reaction; TMN, thin membrane nephropathy.
Fas, FasL, Bcl-2, Bcl-xL, Bax, Bad and Bid mRNA concentration were measured by quantitative real-time PCR and corrected to the housekeeping gene RPL32.
Increased Fas, FasL, and Bid expression was evident in different types of chronic renal disease as compared to controls.
There was no significant difference in Bcl-2, Bcl-xL, Bax, or Bad mRNA concentration between groups.
aPo0.05, bPo0.005, cPo0.0001 versus controls.
Figure 4 | Fas gene expression is increased in chronic renal
disease. Fas mRNA concentration was measured by quantitative
real-time PCR and corrected to the housekeeping gene RPL32. The
ratio of Fas to RPL32 was significantly increased in TMN, IgAN, HTN,
FSGS, and LN versus controls. The mean of each group is represented
by a red line. Abbreviations: RPL32, ribosomal protein L32; TMN, thin
membrane nephropathy; IgAN, IgA nephropathy; HTN, hypertensive
nephropathy; CsAN, cyclosporine A nephropathy; FSGS, focal and
segmental glomerulosclerosis; LN, lupus nephritis. *Po0.05,
***Po0.0001 versus controls.
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The gene expression of these growth factors was also
associated with renal dysfunction. TNFa and TGFb1 mRNA
concentration increased by an estimated 10 and 5%
respectively for every 10 U decrease in eGFR (Po0.05,
Table 7). In contrast, declining renal function was associated
with a decline in EGF expression (approximately 15%
decrease per 10 U decreas in eGFR, Po0.005).
Furthermore, the gene expression of both TGFb1 and
TNFa was associated with the level of proteinuria. The
estimated concentration of TNFa and TGFb1 mRNA was
increased by 8% (95% CI: 0.7–15.0%, P¼ 0.03) and 5% (95%
CI: 1.3–8.1%, P¼ 0.008), respectively, per g/day increase in
proteinuria. EGF mRNA expression was not significantly
associated with the degree of proteinuria. No significant
associations were evident between eGFR or proteinuria and
the expression of the remaining genes examined.
Association between patient outcome and markers of renal
disease and gene expression at the time of biopsy
In an attempt to determine the possible associations between
apoptosis and patient outcome in chronic renal disease, we
examined the relationship between gene expression and
TUNEL score with renal function at follow-up in IgA
nephropathy. Biopsies from patients on minimum of 2 years
follow-up who demonstrated a decline of 5% in eGFR per
year or presented with or progressed to end stage renal failure
were said to have a poor patient outcome compared to
biopsies from patients that had stable or improved renal
function at follow-up. The clinical characteristics of the two
groups of patients defined in this manner (progressors and
nonprogressors) are detailed in the Materials and Methods
section (Table 8).
Greater renal impairment (Table 8) and severity of
tubulointerstitial injury (Po0.0001, Table 9) was evident in
the group with accelerated progressive disease. This was
associated with a higher level of tubulointerstitial apoptosis
as compared to nonprogressors (1.4270.37 versus
0.4570.16 TUNEL-positive cells per mm2 tubulointersti-
tium, P¼ 0.05). Furthermore, the level of glomerular
apoptosis was also increased in progressors versus nonpro-
gressors (0.3670.12 versus 0.0470.02 TUNEL-positive cells
per glomerulus, P¼ 0.05).
When the levels of gene expression were examined,
biopsies with poor outcome had a higher concentration of
TGFb1 and TNFa mRNA (Po0.005, Po0.05 respectively,
Table 10) and a lower concentration of EGF (Po0.05) as
compared to biopsies with stable or improved renal function.
The expression of the other genes examined was not
significantly different between the two groups.
DISCUSSION
The loss of intrinsic renal cells through apoptosis plays an
important role in the development and progression of
chronic renal disease. By examining the gene expression of
apoptotic effector and regulatory molecules in patient
biopsies we attained a greater understanding of the control
of apoptosis in the diseased kidney.
Table 3 | Growth factor gene expression is altered in chronic renal disease
Diagnosis TNFa (mean7s.e.m.) TGFb1 (mean7s.e.m.) IGF-1 (mean7s.e.m.) EGF (mean7s.e.m.)
Control 0.4570.11 1.0170.12 1.4870.35 0.7070.09
TMN 0.4470.13 1.0770.12 6.0071.27c 1.2470.24
IgAN 0.3570.07 0.8370.08 8.6671.42c 0.5370.09
HTN 0.7270.18 1.2870.14 4.9070.80b 0.4070.11
CSAN 1.4470.92 1.5370.50 4.6371.45 0.2970.07a
FSGS 0.6870.18 1.3170.05 5.2871.87a 0.8670.34
LN 0.4570.08 1.2470.16 7.6371.82b 0.7470.14
CsAN, cyclosporine A nephropathy; EGF, epidermal growth factor; FSGS, focal and segmental glomerulosclerosis; HTN, hypertensive nephropathy; IGF, insulin-like growth
factor; LN, lupus nephritis; TGF, transforming growth factor; TMN, thin membrane nephropathy; TNF, tumor necrosis factor.
TNFa, TGFb1, IGF-1, and EGF mRNA concentration were measured by quantitative real-time PCR and corrected to the housekeeping gene RPL32.
Increased IGF-1 mRNA was evident in different types of chronic renal disease as compared to controls.
Significantly decreased EGF mRNA was evident in cyclosporine A nephropathy and a trend toward decreased EGF was evident in hypertensive nephropathy versus controls
(P=0.06). There was no significant difference in TNFa or TGFb1 mRNA between groups.
aPo0.05, bPo0.005, cPo0.0001 versus controls.
Table 4 | Tubulointerstitial apoptosis is associated with
dysregulated growth factor gene expression in chronic renal
disease
Gene of
Interest
Rate ratio (TUNEL-
positive cells/mm2)
95% confidence
interval P-value
Bad 1.31 0.32–5.31 0.70
Bax 2.38 0.61–9.25 0.21
Bcl-2 1.21 0.25–6.00 0.81
Bcl-xL 0.86 0.17–4.39 0.85
Bid 0.89 0.62–1.29 0.54
EGF 0.63 0.42–0.94 0.02
Fas 1.16 0.89–1.50 0.27
FasL 1.00 0.99–1.00 0.85
IGF-1 1.00 0.96–1.06 0.85
TGFb1 2.30 1.07–4.93 0.03
TNFa 1.50 0.73–3.05 0.27
EGF, epidermal growth factor; TGF, transforming growth factor; TUNEL,
TdT-mediated dUTP nick end-labeling assay.
The association between tubulointerstitial TUNEL score and gene expression was
investigated using negative binomial regression modelling, adjusting for gender
and age at biopsy. Results are expressed as the proportional increase in the rate of
apoptotic cells (TUNEL-positive cells/mm2) for every 1 U increase in gene expression.
Tubulointerstitial apoptosis was positively associated with TGFb1 mRNA concentra-
tion and negatively associated with EGF mRNA concentration. There were no
significant associations with the other genes investigated.
Bold values denote the statistically significant results.
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The loss of tubulointerstitial cells through apoptosis was a
common feature of the different chronic renal diseases
examined, irrespective of the underlying cause of disease.
Additionally tubulointerstitial apoptosis was correlated with
the degree of tubulointerstitial injury, proteinuria and decline
in GFR, highlighting the importance of apoptosis in the
development of renal impairment. This is supported by the
increased incidence of apoptosis in biopsies from IgA
nephropathy patients whose disease progressed compared
to those who did not. Thus our data add to the long
established association between tubulointerstitial injury and
renal dysfunction.28,29
A complex relationship exists between proteinuria,
primarily a measure of glomerular basement membrane
function, and tubulointerstitial injury (reviewed in30–32).
Proteinuria alone is able to induce tubular epithelial cell
apoptosis.33,34 The increased injury to tubular epithelial cells
can also result in decreased resorption of protein from the
glomerular filtrate.35,36 Hence the positive correlation found
between proteinuria and tubulointerstitial injury may reflect
proteinuria as being both a mechanism and a result of
Table 5 | Number of patients of each diagnosis per category of tubulointerstitial injury
Tubulointerstitial injury
Disease Very mild Mild to moderate Moderate to severe Total
Thin membrane nephropathy 6 9 0 15
IgA Nephropathy 4 11 8 23
Hypertensive Nephropathy 0 3 7 10
Cyclosporine A Nephropathy 0 4 1 5
Focal and Segmental
Glomerulosclerosis
0 2 3 5
Lupus nephritis 0 4 3 7
Each patient was grouped based on the degree of tubulointerstitial injury reported in the biopsy report written by a senior pathologist at The Alfred Hospital at the time of
diagnosis.
Table 6 | The gene expression of cytokines and growth factors is significantly associated with the severity of tubulointerstitial
injury
Degree of tubulointerstitial injury
Gene of interest
Very mild
(Mean7s.e.m.)
Mild to moderate
(Mean7s.e.m.)
Moderate to severe
(Mean7s.e.m.) P-value
Bad 1.1070.07 1.0770.04 1.1070.04 0.83
Bax 0.9370.05 0.9470.03 1.0370.05 0.22
Bcl-2 0.7870.07 0.7070.03 0.7670.04 0.37
Bcl-xL 0.9070.07 0.8370.05 0.7570.03 0.23
Bid 1.9070.35 1.5870.11 1.4570.16 0.32
EGF 1.2970.32 0.6770.09 0.4870.11 0.04
Fas 2.0570.45 2.0970.17 2.4070.24 0.37
FasL 77.11720.49 63.7679.21 56.54710.99 0.60
IGF-1 8.9972.59 6.0970.64 6.8371.26 0.51
TGFb1 0.7570.12 1.0970.11 1.2470.06 0.004
TNFa 0.2770.13 0.5970.16 0.6270.09 0.004
EGF, epidermal growth factor; IGF, insulin-like growth factor; TGF, transforming growth factor; TNF, tumor necrosis factor.
Fas, FasL, Bcl-2, Bcl-xL, Bax, Bad, Bid, TNFa, TGFb1, IGF-1, and EGF mRNA concentration were measured by quantitative real-time PCR and corrected to the housekeeping gene
RPL32. Number of patients per group: Very Mild n=10, Mild to Moderate n=33 and Moderate to Severe n=22. TNFa and TGFb1 gene expression increased with the severity of
tubulointerstitial injury, whereas EGF mRNA concentration decreased. There was no significant change in gene expression with increasing severity of tubulointerstitial injury
for the other genes examined.
Bold values denote the statistically significant results.
Table 7 | Renal dysfunction is associated with the altered
expression of growth factors and cytokines in chronic renal
disease
Gene of interest
Estimated change in gene expression
per 10 unit decrease in eGFR
(95% confidence interval) P-value
Bad +0.3% (1.4%, +1.8%) 0.76
Bax +1.3% (0.3%, +3.0%) 0.12
Bcl-2 +0.4% (1.9%, +2.7%) 0.71
Bcl-xL 0.4% (2.4%, +1.5%) 0.66
Bid 3.0% (6.7%, +0.7%) 0.12
EGF 14.9% (26.0%, 4.8%) 0.004
Fas +2.5% (1.8%, +6.6%) 0.24
FasL 6.3% (15.7%, +2.3%) 0.15
IGF-1 3.8% (11.2%, +3.0%) 0.28
TGFb1 +5.2% (+1.6%, +8.7%) 0.006
TNFa +9.6% (+2.0%, +16.6%) 0.015
EGF, epidermal growth factor; IGF, insulin-like growth factor; TGF, transforming
growth factor; TNF, tumor necrosis factor.
The association between glomerular filtration rate and gene expression was
investigated using linear regression modelling, adjusting for gender and age at
biopsy. EGF mRNA concentration decreased whereas TNFa and TGFb1 increased
with declining renal function. No significant associations were evident between
eGFR and the other genes investigated.
Bold values denote the statistically significant results.
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tubular injury in chronic renal disease. This is supported by
the positive association found between proteinuria and
expression of the cytokines TNFa and TGFb1.
Apoptotic signals are conveyed through either the
extrinsic death receptor pathway or the intrinsic mitochon-
drial pathway or a combination of the two. In our study
elevated Fas and FasL gene expression was evident in all
chronic renal diseases investigated. However, we were unable
to demonstrate significant associations between Fas or FasL
gene expression and tubulointerstitial injury, apoptosis or
renal dysfunction. Although most well known for its role in
the induction of apoptosis, Fas/FasL signaling is more
complex than solely activating apoptotic signaling cascades.
Under certain circumstances death receptor ligation has been
demonstrated to initiate the activation of nuclear factor kB
and c-Jun N-terminal kinase signalling pathways,37,38 result-
ing in cell survival and pro-inflammatory responses. The
signalling pathway activated upon FasL ligation is partly
controlled by the level of expression of the Fas receptor.39 The
involvement of Fas/FasL signalling has also been reported in
T-cell proliferation.38 Given the lack of association between
Fas/FasL gene expression and renal injury or dysfunction
these alternative nonapoptotic pathways may be activated in
chronic renal disease.
The expression of the pro-apoptotic Bcl-2 family member
Bid, which links the mitochondrial pathway to the death
receptor pathway, was also increased in chronic renal disease.
In this study no consistent changes were evident in the
expression of other genes of the Bcl-2 family. Given that the
Bcl-2 family are central players in the regulation of apoptosis
the lack of any significant association between their
expression and tubulointerstitial apoptosis, injury or renal
dysfunction was surprising. This may be due to localised
changes in expression being ‘evened out’ over the whole of
the biopsy. We have previously described this in the
puromycin aminonucleoside model of focal and segmental
glomerulosclerosis, where Bcl-2 mRNA is increased segmen-
tally in some glomeruli and is also expressed by infiltrating
leukocytes, however there is no significant change in the total
level of renal Bcl-2 mRNA compared to the controls.40 It is of
importance to note that it is not merely the level of
expression of Bcl-2 family members that determines the fate
of the cell but also their localization, post-translational
processing (including cleavage of Bid by caspases41,42 and
de-phosphorylation of Bad43,44) and the overall balance
between pro and anti-apoptotic factors.
Significant associations were found between the expres-
sion of TNFa and TGFb1 and tubulointerstitial injury and
Table 8 | Clinical characteristics of IgA nephropathy patients with either progressive or nonprogressive disease at the time of
biopsy and follow-up
At biopsy At follow-up
Number
of patients
(male, female)
Age
at biopsy
median (range)
Follow-up years
median
(range)
SerCr mmol/l
median
(range)
eGFR ml/min/
1.73m2
median
(range)
Proteinuria
g/24 h
Median
(Range)
SerCr mmol/l
median
(range)
eGFR ml/min/
1.73m2
median
(range)
Proteinuria
g/24 h
median
(range)
Nonprogressors 11 (6, 5) 26 (19–65) 3 (2–4) 0.08 (0.05–0.10) 87 (66–147) 0.58 (0.17–1.77) 0.09 (0.06–0.12) 82 (57–116) 0.24 (0.05–4.39)
Progressors 11 (7, 4) 55 (38–75) 3.5 (2–4) 0.14 (0.08–0.40) 50 (11–76) 2.26 (0.71–6.00) 0.15a (0.10–0.35) 45a (16–56) 1.92a (0.19–4.34)
P-value 0.748 0.001 0.310 0.001 0.0001 0.005 0.0001 0.0001 0.016
Patients whose disease progressed had significantly decreased renal function and increased proteinuria at both the time of biopsy and at last follow-up as compared to those
whose disease did not progress.
aMedian and range of eight patients as three were on renal replacement therapy.
Table 9 | Progressors have a greater degree of
tubulointerstitial injury at biopsy compared to
nonprogressors
Degree of tubulointerstitial injury
Very mild
Mild to
moderate
Moderate
to severe
Total number
of patientsa
Nonprogressors 4 7 0 11
Progressors 0 3 8 11
The degree of tubulointerstitial injury was determined from the biopsy report
written by a senior pathologist at The Alfred Hospital at the time of diagnosis. IgA
nephropathy patients whose disease progressed were found to have a greater
degree of tubulointerstitial injury at the time of biopsy compared to those whose
disease did not progress (Po0.0001).
aOne out of the total of 23 IgA nephropathy patients was lost to follow-up.
Table 10 | Dysregulated cytokine and growth factor gene
expression is associated with poor patient outcome in IgA
nephropathy
Gene of interest
Nonprogressor
mean7s.e.m.
Progressor
mean7s.e.m. P-value
Bad 1.0970.07 1.0670.07 0.73
Bax 0.9670.06 0.9770.05 0.85
Bcl-2 0.6870.07 0.7270.07 0.69
Bcl-xL 0.9270.13 0.6870.04 0.30
Bid 2.0770.29 1.4670.24 0.06
EGF 0.7370.16 0.3370.06 0.04
Fas 2.4670.44 2.2270.38 0.80
FasL 107.38722.89 62.95718.66 0.15
IGF-1 9.9871.99 7.4572.23 0.22
TGFb1 0.6370.11 1.0670.08 0.004
TNFa 0.2670.11 0.4570.10 0.02
EGF, epidermal growth factor; IGF, insulin-like growth factor; TGF, transforming
growth factor; TNF, tumor necrosis factor.
Bad, Bax, Bcl-2, Bcl-xL, Bid, EGF, Fas, FasL IGF-1, TGFb1 and TNFa mRNA concentration
was measured by quantitative real-time PCR and corrected to the housekeeping
gene RPL32. There were 11 patients per group. TGFb1 and TNFa expression was
elevated in Progressors as compared to Nonprogressors, whereas EGF expression
was decreased. The other genes examined were not significantly different between
the two groups.
Bold values denote the statistically significant results.
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renal dysfunction. In chronic renal disease the production of
TNFa and other pro-inflammatory cytokines by activated
immune cells results in the release of chemoattractant
molecules by tubular epithelial cells.45 This further recruits
leukocytes to the tubulointerstitium, enhancing inflamma-
tion, tubulointerstitial damage, and renal dysfunction.
Similarly our finding of a positive association between
TGFb1 expression and the severity of tubulointerstitial injury
and renal dysfunction is supported by studies in which hyper-
expression of TGFb1 in African Americans is associated with
increased risk of progression from chronic renal disease to
end-stage renal failure.46,47 TGFb1 contributes to tubuloin-
terstitial injury and renal dysfunction through the loss of
tubular epithelial cells, by both potentiating48,49 and inducing
apoptosis23 and by inducing their transformation into
fibroblasts.50 Furthermore, TGFb1 is known to promote
renal dysfunction through the up-regulation of pro-fibrotic
growth factors.51–54
Our data showed an increase in IGF-1 mRNA in chronic
renal disease as compared to controls but failed to
demonstrate any significant associations between IGF-1
mRNA concentration and tubulointerstitial apoptosis, injury,
or renal dysfunction. It has been demonstrated in rats that
the systemic administration of either TNFa or IL-1b will
increase the expression of IGF-1 in the kidney.55,56 Therefore
the presence of these cytokines, which are expressed by
infiltrating inflammatory cells, may be responsible for the up-
regulation of IGF-1 gene expression evident in patient
biopsies as compared to controls. This increase in IGF-1 is
in sharp contrast to the expression of the other survival factor
examined, EGF, which was decreased in both cyclosporine A
and hypertensive nephropathy versus controls. Furthermore,
EGF expression declined with the severity of tubulointerstitial
injury and was negatively associated with both tubulointer-
stitial apoptosis and renal dysfunction. As EGF also promotes
tubular epithelial cell proliferation,57 the downregulation of
EGF in chronic renal disease may leave tubular epithelial cells
more vulnerable to apoptotic insults and less able to repair
damaged tubules, ultimately leading to tubular atrophy. This
is supported by in vitro studies in which EGF protects renal
epithelial cells from serum deprivation20 and Fas induced
apoptosis21 and in vivo studies where exogenous EGF
administration protects against tubulointerstitial injury, by
both decreasing apoptosis and increasing proliferation of
tubular epithelial cells.58–60 Our results suggest that in the
setting of chronic renal disease EGF may be a more
important survival factor than IGF-1.
In IgA nephropathy the correlation between disease
progression and the extent of renal impairment, proteinuria
and histological lesions at initial biopsy is well documen-
ted61–63 and supports our current findings. The increased
TGFb1 and TNFa expression and decreased expression of
EGF in IgA nephropathy patients whose disease progressed as
compared to those that did not support our findings on the
importance played by these growth factors in chronic renal
disease generally.
The localization of the cytokines and growth factors that
were significantly associated with histological and clinical
markers of renal disease has previously been determined. Our
group has demonstrated that there is decreased tubular
expression of EGF in areas of damage in chronic renal
transplant rejection64 and similar results have been reported
in chronic renal disease.65,66 TGFb1, Fas, FasL, and Bax are
expressed by intrinsic renal cells in areas of damage, notably
by tubular epithelial cells, but also by interstitial inflamma-
tory cells.9,67 TNFa is expressed by infiltrating leukocytes,
predominantly of the monocyte/macrophage lineage.68 The
localization of much of the apoptotic machinery, for example
Bad and Bid, has not been widely investigated in chronic
renal disease.
In this study, we demonstrate that in chronic kidney
disease renal dysfunction is associated with increased
apoptosis and the upregulated expression of the proapoptotic
cytokines TNFa and TGFb1 and downregulated expression of
the survival factor EGF. Any novel therapies that could limit
the loss of intrinsic renal cells through apoptosis and/or
correct the dysfunctional expression of cytokines/growth
factors may delay or halt the progression of chronic renal
disease, improving patient outcomes.
MATERIALS AND METHODS
Patients and renal biopsies
Clinical characteristics of the patients whose biopsy tissue was used
in this study are detailed in Table 11. Serum creatinine (SerCr)
concentration was determined at the time of biopsy and the degree
of proteinuria measured by 24 h urine collection. The eGFR was
calculated from the serum creatinine concentration using the
simplified MDRD (Modification of Diet in Renal Disease) equation
(Levey et al. J Am Soc Nephrol 11: A8028, 2000). Control renal tissue
was obtained from the uninvolved pole of tumour nephrectomies or
kidneys unsuitable for transplantation. Tissue for RNA extraction
was snap frozen in liquid nitrogen and stored at 801C until the
extractions were performed. The remaining tissue was formalin-
fixed and paraffin-embedded by the Department of Anatomical
Pathology at the Alfred Hospital. Serial sections were cut and
examined histologically for diagnostic purposes.
The degree of tubulointerstitial damage evident in the renal
biopsies was documented in the Biopsy Report by a senior
pathologist at The Alfred Hospital at the time of patient diagnosis.
For this study the renal biopsies were grouped according to these
comments. The groups were Very Mild Injury, Mild to Moderate
Injury and Moderate to Severe Injury. An estimate of the percent of
tubulointerstitial area affected in each grade was: o20%, o70%,
and 470%, respectively. The distribution of the degree of
tubulointerstitial damage evident in each disease group is described
in Table 5. Control renal tissue was examined by the pathologist and
found to be histologically normal.
Additionally, patients from the IgA nephropathy group were
defined as ‘progressors’ or ‘nonprogressors’ based on their renal
function at follow-up. This group was chosen to investigate the
relationship between patient outcome and gene expression as it
had the greatest number of patients and follow-up data were
available. Given the slow rate of progression that can be observed in
IgA nephropathy it was decided that a minimum of 2 years
follow-up with stable renal function was required for a patient to be
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defined as a nonprogressor. If a patient had significant renal
impairment at presentation, but renal function was within the
normal range (1.5–2.5 ml/s) at last follow-up they were also defined
as nonprogressors. Progressors had a significant decline in renal
function from the baseline measured at the time of renal biopsy.
To be defined as significant the average decline in eGFR had to be
greater than 5% per year and below the normal range at the time of
last follow-up. All who required renal replacement therapy were
defined as progressors (i.e., those that presented with severe renal
failure).
Ethics approval was obtained from the Alfred Hospital Ethics
Committee before the commencement of the project. At the time of
biopsy written informed consent was received from the patients for
the use of any excess biopsy tissue for research purposes.
RNA extraction and quantitative real-time polymerase
chain reaction
Frozen biopsy sections for RNA extraction were placed in a dewar
containing liquid nitrogen before homogenization in extraction
buffer with a Polytron homogeniser (Kinetmatica AG, Littau-
Lucerne, Switzerland). RNA extractions were then performed using
the Qiagen RNeasy Mini Kit (Qiagen Pty Ltd, Clifton Hill, VIC,
Australia) as per the manufacturers’ instructions. RNA concentra-
tion was determined using a Nanodrop ND-1000 spectrophot-
ometer (Nanodrop Technologies Inc., Wilmington, DE, USA) and
all samples were diluted to 5 ng/ml RNA. Diluted RNA (2ml) was
added per 18 ml reverse transcription mix (final concentrations:
4 mM dNTP, 5 mM MgCl2, 1 reverse transcription buffer, 1 U
RNAse inhibitor, 2.5 U multiscribe enzyme, and 2.5 mM random
hexamers). All PCR reagents, excluding primers, were obtained from
Applied Biosystems (Applied Biosystems, Foster City, CA, USA).
After reverse transcription, mRNA concentration was assessed by
quantitative real-time PCR on an ABI Prism 7900HT Sequence
Detection System (Applied Biosystems) using a standard curve
method. The primer and probe sequences are shown in Table 12.
About 1 ml cDNA was added per 9 ml PCR mix (final concentrations:
1 buffer A, 6.25 mM MgCl2, 1.2 mM dNTPs, 900 mM forward
primer, 900 mM reverse primer, 250 mM Taqman Probe, 0.5 U
AmpliTAQ Gold). Real-time PCR primers were synthesized by
Geneworks (Geneworks Pty Ltd, Thebarton, SA, Australia). Results
were standardized to the housekeeping gene Ribosomal Protein L32
(RPL32).
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end-labelling technique
1.5-mm-thick sections of paraffin-embedded renal biopsy tissue were
dewaxed, rehydrated, and washed in phosphate-buffered saline
(PBS). Sections were then incubated with terminal deoxynucleotidyl
transferase (TdT) buffer (Promega US, Madison, MI, USA) for
10 min at room temperature before incubation with TdT enzyme
(Promega) and DIG-labelled dUTP (Roche Diagnostics Australia
Pty Ltd, Castle Hill, NSW, Australia) for 60 min at 371C in a moist
chamber. After blocking endogenous peroxidase activity nonspecific
antibody binding was blocked with 20% normal rabbit serum
(NBS)/PBS/0.01% azide (Az) for 10 min. Sections were drained and
incubated with a peroxidase conjugated rabbit anti-DIG antibody
(DAKO Corp., Carpinteria, CA, USA) diluted in 5% normal human
serum/1% NBS/PBS/Az for 60 min at room temperature. Signal was
developed using the Diaminobenzidine (DAB) Metal Enhanced
Substrate Kit (Pierce Biotechnology Inc., Rockford, IL, USA).
Table 11 | Patient’s clinical characteristics
Diagnosis
Number of patients
(male, female)
Age at biopsy
median (range)
SerCr mmol/l
median (range)
eGFR ml/min/1.73 m2
median (range)
Proteinuria g/day
median (range)
Control 8 (4, 4) 57 (41–71) NA NA NA
Thin membrane nephropathy 15 (4, 11) 45 (19–68) 0.08 (0.06–0.12) 83 (41–116) 0.17 (0.09–1.11)
IgA nephropathy 23 (14, 9) 41 (19–75) 0.10 (0.05–0.40) 66 (11–147) 1.12 (0.17–6.00)
Hypertensive nephropathy 10 (7, 3) 70 (38–80) 0.19 (0.15–0.70) 24 (8–45) 2.08 (0.10–17.35)
Cyclosporine A nephropathy 5 (4, 1) 52 (34–54) 0.24 (0.14–0.27) 26 (23–49) 0.60 (0.10–4.00)
Focal and segmental glomerulosclerosis 5 (4, 1) 49 (28–65) 0.16 (0.08–0.26) 48 (17–98) 3.00 (0.33–10.00)
Lupus nephritis 7 (2, 5) 42 (32–52) 0.08 (0.07–0.10) 74 (59–85) 1.70 (0.37–14.71)
NA, not available.
Table 12 | Nucleotide sequences of real-time PCR primers and probes
Gene Forward primer (50–30) Reverse primer (50–30) Probe (50–30)
Bad CCTCAGGCCTATGCAAAAAGAG CGCACCGGAAGGGAATC 6FAM-ATCCGTGCTGTCTCC-MGBNGQ
Bax ACCAAGGTCCCGGAACTG CAACCACCCTGGTCTTGGAT 6FAM-CATTGGACTTCCGGGA-MGBNFQ
Bcl-xL GTGCGTGGAAAGCGTAGACAA GGCTCTAGGTGGTCATTCAGGTAA 6FAM-ATGCAGGTATTGGTGAGTC-MGBNFQ
Bcl-2 CATGTGTGTGGAGAGCGTCAA GCCGGTTCAGGTACTCAGTCA 6FAM-TGGACAACATCGCCCTGTMG-BNFQ
Bid GATGCCCCGGGAGTTAGC GCATGGATGAGCTGAGCGTAT 6FAM-CCCCTGGTAATAGC-MGBNFQ
EGF AATGCCAGCTGCACAAATACAG CTTACGGAATAGTGGTGGTCATCTT 6FAM-AGGGAGGCTATACCTG-MGBNFQ
Fas TGGTGGACCCGCTCAGTAC CCAGCATGGTTGTTGAGCAA 6FAM-AGCTCTTTCACTTCGGAG-MGBNFQ
FasL TGCCTCCTCTTGAGCAGTCA TCCTGTAGAGGCTGAGGTGTCA 6FAM-CAACAGGGTCCCGTCC-MGBNFQ
IGF-1 GGAAGTACATTTGAAGAACGCAAGTA TGCGGTGGCATGTCACTCT 6FAM-CAGGATGTAGGAAGACC-MGBNFQ
RPL32 CACCAGTCAGACCGATATGTCAA TTGTCAATGCCTCTGGGTTTC 6FAM-ATTAAGCGTAACTGGCG-MGBNFQ
TGFb1 CACCCGCGTGCTAATGG ATGCTGTGTGTACTCTGCTTGAACT 6FAM-CCACAACGAAATCTA-MGBNFQ
TNFa CTCGAACCCCGAGTGACAAG GGAGCTGCCCCTCAGCTT 6FAM-ATGTTGTAGCAAACCCT-MGBNFQ
FAM, fluorescent reporter dye; IGF, insulin-like growth factor; MGBNFQ, minor groove binder and non-fluorescent quencher dye; TGF, transforming growth factor; TNF, tumor
necrosis factor; PCR, polymerase chain reaction.
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Cells were considered apoptotic on the basis of positive
TUNEL staining and morphological changes including condensa-
tion and marginalization of nuclei (for example see Figure 3).
The apoptotic cells from the entire biopsy section were counted
under light microscope with the use of a graticule at  400
magnification. Negative controls without TdT enzyme and positive
controls with DNase treatment were included for each tissue.
Staining was repeated with 0.015% protease VIII pretreatment for
1 min if the positive control of the undigested TUNEL staining was
too pale.
Statistical analysis
Gene expression in chronic renal disease was compared to the
control group by analysis of variance followed by planned contrasts
using SPSS for Windows software version 12.0 (SPSS Inc., Chicago,
IL, USA). Markers of renal disease and gene expression were
compared between patients with nonprogressive and progressive IgA
nephropathy using a t-test or a Mann–Whitney test as appropriate.
All remaining statistical analysis was performed using STATA for
Windows software version 9 (StataCorp., College Station, TX, USA).
The relationship between gene expression and tubulointerstitial
injury or renal function was examined using linear regression
models. Gene expression variables were log-transformed to conform
to the assumptions of the regression models. The association
between tubulointerstitial apoptosis and renal function or gene
expression was examined using negative binomial regression models.
Models were adjusted for sex and age at biopsy in each case.
A P-value less than 0.05 was considered statistically significant.
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